MYGN Stock Analysis: Buy, Sell, or Hold?
MYGN - Myriad Genetics Inc
$5.22
0.59 (12.74%)
▲
5d:
+22.82%
30d:
+36.65%
90d:
+13.23%
HOLD
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When MYGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: MYGN is 12.5% above its trading range ($4.64). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: MYGN is 12.5% above its trading range ($4.64). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: MYGN is currently trading at $5.22, which is considered extended relative to its 30-day fair value range of $3.91 to $4.64. From a valuation perspective, the stock is trading at a discount (Forward PE: 34.5) compared to its historical average (52.8). Remarkably, the market is currently pricing in an annual earnings decline of 13.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, MYGN is in a downtrend. The price is approaching resistance at $5.17. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 12.7% recently.
Market Sentiment: MYGN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.25 (+19.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, MYGN is in a downtrend. The price is approaching resistance at $5.17. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 12.7% recently.
Market Sentiment: MYGN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.25 (+19.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.91 -
$4.64
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
54.8%
Protect Your Profits
Holding MYGN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+12.5% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+12.7%)
- BULLISH: Trading below Wall St target ($6.25)
Trading Range Analysis
30-Day Trading Range
$3.91 -
$4.64
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$4.19
Resistance Level
$5.18
Current Trend
Downtrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
34.55
Wall Street Target
$6.25
(+19.7%)
Revenue Growth (YoY)
-20.8%
Profit Margin
-41.3%
Valuation Discount vs History
-13.2% cheaper
PE vs Historical
34.6 vs 52.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-13.2%
(market-implied from PE analysis)
1-Year Target
$4.70
(-10%)
2-Year Target
$4.23
(-19%)
3-Year Target
$3.81
(-27%)
3-Yr Target (if PE normalizes)
(PE: 35→53)
$5.82
(+11%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 34.5, Growth: 216.1%)
$17.62
(+238%)
Base:
(SPY PE: 21.8, Growth: 216.1%)
$11.11
(+113%)
Bear:
(PE: 18.5, Growth: 216.1%)
$9.44
(+81%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 34.5 to 52.8
Stabilization Target:
$7.98
(+52.8%)
PE Expansion Potential:
+52.8%
Share & Embed Analysis
Last updated: June 24, 2026 6:54 PM ET
Data refreshes hourly during market hours. Next update: 7:54 PM
Data refreshes hourly during market hours. Next update: 7:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MYGN showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Samraat S Raha
BUY
40000 shares
2026-03-09
S. Louise Phanstiel
BUY
48000 shares
2026-02-27
S. Louise Phanstiel
BUY
50407 shares
2026-02-26
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$599 | 62 BUY |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$242 | 66 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$142 | 56 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$260 | 65 BUY |
Advanced MYGN Option Strategies
Professional options setups generated by AI based on today's MYGN price and gamma walls.
